Valuation: Healios K.K.

Market Cap 30.23B 191M 171M 156M 143M 269M 17.94B 278M 1.89B 752M 9.57B 717M 701M P/E 2026 *
-5.79x
P/E 2027 * -8.2x
Enterprise Value 35.96B 227M 204M 186M 170M 320M 21.35B 330M 2.24B 895M 11.39B 852M 834M EV / Sales 2026 *
91.9x
EV / Sales 2027 * 11.6x
Free-Float
79.1%
Yield 2026 *
-
Yield 2027 * -
10-05 Healios Completes First 144 Million Yen Culture Supernatant Shipment to JENECEL MT
09-30 Healios K.K. Announces Shipment Timing of Initial Order of Culture Supernatant Products to JENECELL CI
07-27 Healios Announces Selection of Akt-01/Hlcn061 Commercial Manufacturing Process for Amed Project CI
04-08 Japan Stocks Rise as US-Iran Ceasefire Eases Geopolitical Concerns MT
04-07 Healios Secures 144 Million Yen Initial Order from Alfresa's Korean Unit for Cosmetic Raw Material MT
04-07 Healios to Supply Stem Cell Culture Material to JENECELL in Cosmetics Deal MT
04-07 Healios K.K. Enters Agreement with Jenecell to Supply Culture Supernatant CI
03-27 Healios K.K. Receives Grant Approval from Ministry of Economy, Trade and Industry for Subsidy Program to Support Capital Investment in Regenerative, Cell, and Gene Therapy Manufacturing Facilities CI
02-20 Healios Plans Capital Reduction to Eliminate Retained Losses MT
02-13 Healios K.K. announced that it has received ¥6.2985881 billion in funding from Athos Capital Limited, New Holland Capital, LLC, Lighthouse Investment Partners, LLC, Walleye Capital LLC CI
02-03 Healios K.K. Announces Start of ARDS Clinical Trial in Japan for the Global Phase 3 REVIVE-ARDS Study CI
01-29 Healios K.K. announced that it expects to receive ¥6.2985881 billion in funding from Athos Capital Limited, New Holland Capital, LLC, Lighthouse Investment Partners, LLC, Walleye Capital LLC CI
01-21 Healios Signs LOI with Alfresa for Ongoing Supply of Stem Cell Culture Supernatant MT
1 day-8.98%
1 week-18.32%
Current month-18.32%
1 month-26.89%
3 months-9.72%
6 months-35.55%
Current year-18.61%
1 week 218
Extreme 218
268
1 month 218
Extreme 218
304
Current year 208
Extreme 208
483
1 year 208
Extreme 208
499
3 years 114
Extreme 114
747
5 years 114
Extreme 114
1,712
10 years 114
Extreme 114
2,557
Manager TitleAgeSince
Chief Executive Officer 49 01/03/2018
Director of Finance/CFO 50 16/07/2019
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Director/Board Member 49 01/02/2012
Director/Board Member 50 01/03/2018
Director/Board Member 73 01/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
-8.98%-18.32%-52.25%+31.18% 191M
-4.83%+3.51%+55.00%+63.79% 66.7B
+0.02%+1.07%+11.72%+75.63% 56.88B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
-2.97%-9.84%+90.91%+73.49% 33.29B
+5.19%+1.62%-39.69%+368.87% 25.1B
Average +0.12%+0.55%+39.04%+170.51% 40.69B
Weighted average by Cap. +0.65%+3.06%+49.85%+165.81%

Financials

2026 *2027 *
Net sales 392M 2.47M 2.22M 2.03M 1.85M 3.49M 232M 3.6M 24.43M 9.74M 124M 9.28M 9.08M 3.2B 20.22M 18.14M 16.58M 15.13M 28.51M 1.9B 29.41M 200M 79.67M 1.01B 75.9M 74.27M
Net income -3.75B -23.66M -21.22M -19.4M -17.7M -33.36M -2.22B -34.41M -234M -93.22M -1.19B -88.81M -86.91M -2.82B -17.81M -15.97M -14.6M -13.32M -25.1M -1.67B -25.89M -176M -70.15M -893M -66.83M -65.4M
Net Debt 5.73B 36.21M 32.48M 29.68M 27.1M 51.05M 3.4B 52.66M 358M 143M 1.82B 136M 133M 7B 44.21M 39.65M 36.24M 33.08M 62.32M 4.16B 64.29M 437M 174M 2.22B 166M 162M
Projected Income Statement - Annual - Healios K.K.
Logo Healios K.K.
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
Employees
75
Date Price Change Volume
06/11/26 ¥223.00 -8.98% 3,557,600
05/11/26 ¥245.00 -3.54% 1,956,000
04/11/26 ¥254.00 -2.68% 2,078,700
02/11/26 ¥261.00 -4.40% 1,195,600
30/10/26 ¥273.00 -1.80% 657,600
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Healios K.K.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
223.00JPY
Average target price
794.83JPY
Spread / Average Target
+256.43%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Healios K.K.
  1. Stock Market
  2. Stocks
  3. 4593 Stock